| Document Date: 2012-11-29 23:47:05
Open Document File Size: 321,74 KBShare Result on Facebook
City Sydney / / Company Advanced Cell Technologies / AMD / Allergan Inc. / / Continent Europe / / Country Italy / New Zealand / United States / Australia / United Kingdom / Greece / / Currency USD / / Event FDA Phase / Product Issues / / Facility Westmead Millennium Institute / / IndustryTerm manufacturing dossier / food / energy / low energy laser / Waste products / toxic waste products / / MedicalCondition Macular Degeneration / very complex disease / slow disease / Stargardt’s disease / cancer / disease / early Age-related Macular Degeneration / total blindness / diseases / Dry Macular Degeneration / inflammation / vision threatening disease / / MedicalTreatment retreatment / Intravenous infusion / Gene therapy / / Organization US Federal Drug Administration / Blackmore Foundation / Macular Degeneration Foundation / Westmead Millennium Institute / / Person Robyn Guymer / Liubov Robman / Shinya Yamanaka / Jean Morton / Safety / Paul Mitchell / Paul Beaumont / / / Position eye specialist / Professor / / Product Eye injection / Intravitreal injection / Lucentis / Copaxone / iSONEP 2 Eye / This / eye / E10030 / RN6G / Federal Drug / gene / Stargardt / / ProvinceOrState Maryland / / Technology transplantation / Stem cells / ATG / Gene therapy / laser / / URL www.mdfoundation.com.au / /
SocialTag |
Research Update December 2012 This update is a summary of some of the latest developments in Macular Degeneration (MD) research. This is an area of significant investment and effort, and some research projects are showin